Frédéric Haesebaert1,2, Rémi Moirand1,2, Anne-Marie Schott-Pethelaz3, Jérôme Brunelin1,2, Emmanuel Poulet1,2,4. 1. a INSERM U1028, CNRS UMR5292, Lyon Neuroscience Research Center, ΨR2 Team , University Lyon , France. 2. b Centre Hospitalier Le Vinatier , Bron , France. 3. c Pôle "Information Médicale Evaluation Recherche" (IMER) , Lyon , France. 4. d Service de Psychiatrie des urgences , CHU Lyon, Hôpital Edouard Herriot , Lyon , France.
Abstract
OBJECTIVES: To investigate the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS), venlafaxine or a combination of both treatments as a maintenance treatment in patients with treatment-resistant depression (TRD). METHODS: In a three-arm open-label study, 66 patients, including 45 remitters, who responded torTMS (n = 25), venlafaxine (n = 22), or a combination of both treatments (n = 19) continued to receive the treatment that led to a response as a maintenance treatment over 12 months. Maintenance rTMS was administered twice per week for 1 month, once per week for 2 months, and once every 2 weeks for 9 months. Venlafaxine was maintained at the dose that induced a clinical response (150 or 225 mg/day). RESULTS: After the 12-month follow-up, the rates of remitters (HDRS < 8) were not different between the three groups (χ2 = 1.25; P = .3). The rates of patients who not relapsed (HDRS < 15) were not different between groups (χ2 = 0.33; P = .8): 40.0% in the rTMS group, 45.1% in the venlafaxine group and 36.9% in the combination group. CONCLUSIONS: The three maintenance approaches exhibited similar efficacies in relapse prevention and the maintenance of remission in patients with TRD.
RCT Entities:
OBJECTIVES: To investigate the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS), venlafaxine or a combination of both treatments as a maintenance treatment in patients with treatment-resistant depression (TRD). METHODS: In a three-arm open-label study, 66 patients, including 45 remitters, who responded to rTMS (n = 25), venlafaxine (n = 22), or a combination of both treatments (n = 19) continued to receive the treatment that led to a response as a maintenance treatment over 12 months. Maintenance rTMS was administered twice per week for 1 month, once per week for 2 months, and once every 2 weeks for 9 months. Venlafaxine was maintained at the dose that induced a clinical response (150 or 225 mg/day). RESULTS: After the 12-month follow-up, the rates of remitters (HDRS < 8) were not different between the three groups (χ2 = 1.25; P = .3). The rates of patients who not relapsed (HDRS < 15) were not different between groups (χ2 = 0.33; P = .8): 40.0% in the rTMS group, 45.1% in the venlafaxine group and 36.9% in the combination group. CONCLUSIONS: The three maintenance approaches exhibited similar efficacies in relapse prevention and the maintenance of remission in patients with TRD.
Entities:
Keywords:
DLPFC; Depression; maintenance treatment; rTMS; transcranial magnetic stimulation
Authors: Joseph J Taylor; John H Krystal; Deepak C D'Souza; Jason Lee Gerrard; Philip R Corlett Journal: Schizophr Res Date: 2017-09-29 Impact factor: 4.939
Authors: Chris Baeken; Anna-Katharine Brem; Martijn Arns; Andre R Brunoni; Igor Filipčić; Ana Ganho-Ávila; Berthold Langguth; Frank Padberg; Emmanuel Poulet; Fady Rachid; Alexander T Sack; Marie-Anne Vanderhasselt; Djamila Bennabi Journal: Curr Opin Psychiatry Date: 2019-09 Impact factor: 4.741